# EA2201 (NCT04751370)

> Testing Nivolumab and Ipilimumab With Short-Course Radiation in Locally Advanced Rectal Cancer

No report yet. It can be ordered.

- Drugs tested: nivolumab plus ipilimumab
- Indication: MSI-H/dMMR locally advanced rectal adenocarcinoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04751370
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: National Cancer Institute (NCI)
- Conditions: Locally Advanced Rectal Adenocarcinoma; Stage II Rectal Cancer AJCC v8; Stage III Rectal Cancer AJCC v8
- Interventions: Computed Tomography; Ipilimumab; Magnetic Resonance Imaging; Nivolumab; Radiation Therapy; Sigmoidoscopy; Total Mesorectal Excision
- Enrollment: 31
- Primary outcome: Pathological complete response

## Indexed commentary on EA2201 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 14

## Order

Standard, $1,250 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=ea2201-nct04751370

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04751370", "email": "<work email>"}; the inbox owner confirms by the emailed link.